These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1186 related items for PubMed ID: 28596043

  • 1. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.
    Lancet; 2017 Jul 15; 390(10091):276-288. PubMed ID: 28596043
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.
    Lancet; 2018 Aug 25; 392(10148):650-661. PubMed ID: 30097359
    [Abstract] [Full Text] [Related]

  • 3. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R, OPT Compare Investigators.
    Lancet; 2015 Aug 08; 386(9993):552-61. PubMed ID: 26051365
    [Abstract] [Full Text] [Related]

  • 4. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A, Nakagawa H, Morita A, Okubo Y, Sano S, Imafuku S, Tada Y, Honma M, Mendelsohn AM, Kawamura M, Ohtsuki M.
    J Dermatol; 2021 Jun 08; 48(6):853-863. PubMed ID: 33630387
    [Abstract] [Full Text] [Related]

  • 6. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE.
    Am J Clin Dermatol; 2019 Apr 08; 20(2):295-306. PubMed ID: 30924030
    [Abstract] [Full Text] [Related]

  • 7. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R.
    Br J Dermatol; 2015 Oct 08; 173(4):930-9. PubMed ID: 26042589
    [Abstract] [Full Text] [Related]

  • 8. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D.
    Br J Dermatol; 2020 Mar 08; 182(3):605-617. PubMed ID: 31218661
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S, Nakagawa H, Igarashi A, Morita A, Okubo Y, Sano S, Tada Y, Nemoto O, Rozzo SJ, Kawamura M, Ohtsuki M.
    J Dermatol; 2021 Jun 08; 48(6):844-852. PubMed ID: 33523513
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA, Reich K, Blauvelt A, Kimball AB, Gooderham M, Tyring SK, Sinclair R, Thaci D, Li Q, Cichanowitz N, Green S, La Rosa C.
    J Eur Acad Dermatol Venereol; 2019 Jun 08; 33(6):1098-1106. PubMed ID: 30838709
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, Weibel L, Philipp S, Ghislain PD, Landells I, Hoeger P, Kotkin C, Unnebrink K, Seyger M, Williams D.
    Lancet; 2017 Jul 01; 390(10089):40-49. PubMed ID: 28478975
    [Abstract] [Full Text] [Related]

  • 12. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 01; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
    Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, Blauvelt A.
    Br J Dermatol; 2020 Jun 01; 182(6):1359-1368. PubMed ID: 31487406
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA.
    Br J Dermatol; 2011 Sep 01; 165(3):652-60. PubMed ID: 21574983
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA.
    Br J Dermatol; 2011 Sep 01; 165(3):661-8. PubMed ID: 21574984
    [Abstract] [Full Text] [Related]

  • 16. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 17. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C.
    Lancet; 2019 Aug 17; 394(10198):576-586. PubMed ID: 31280967
    [Abstract] [Full Text] [Related]

  • 18. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
    Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K.
    Br J Dermatol; 2021 Aug 17; 185(2):323-334. PubMed ID: 33544883
    [Abstract] [Full Text] [Related]

  • 19. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.
    Fernandez AP, Dauden E, Gerdes S, Lebwohl MG, Menter MA, Leonardi CL, Gooderham M, Gebauer K, Tada Y, Lacour JP, Bianchi L, Egeberg A, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Mehta NN.
    J Eur Acad Dermatol Venereol; 2022 Oct 17; 36(10):1774-1783. PubMed ID: 35460287
    [Abstract] [Full Text] [Related]

  • 20. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
    Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, Gordon KB, Merola JF, Okubo Y, Madden C, Wang M, Cioffi C, Vanvoorden V, Lebwohl M.
    Lancet; 2021 Feb 06; 397(10273):487-498. PubMed ID: 33549193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.